Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SynAct Pharma AB ( (SE:SYNACT) ) has provided an update.
SynAct Pharma has announced an updated composition of its Nomination Committee ahead of the company’s 2026 Annual General Meeting, reflecting changes since the initial committee was presented in December 2025. The committee now includes Chairman of the Board Anders Kronborg alongside representatives appointed by TJ Biotech ApS, Sanos ApS, and Hunter Capital, whose proposals will be detailed in the forthcoming AGM notice for the meeting scheduled on June 11, 2026.
The revised Nomination Committee structure underscores the continued involvement of key shareholders and board leadership in shaping SynAct Pharma’s governance and board composition. This process is likely to influence the company’s strategic direction and oversight at a time when its clinical-stage anti-inflammatory pipeline and market positioning in melanocortin-based therapies remain central to its long-term value creation for investors and other stakeholders.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on resolving inflammation by selectively activating the melanocortin system. The company is developing a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation-resolving activity, aiming to help patients restore immune balance and address inflammatory conditions.
Average Trading Volume: 189,399
Technical Sentiment Signal: Sell
Current Market Cap: SEK915.1M
Learn more about SYNACT stock on TipRanks’ Stock Analysis page.